



Press release

Stockholm, 30 June 2017

New major order from China

Bactiguard has received a third major order from China of 100 000 Bactiguard coated Foley catheters for infection prevention, which will be delivered in June and generate revenues of some 3 million SEK.

We have received a third major order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention (BIP Foley), which is the same quantity as the first two orders received after product approval in China and delivered in 2016. The order will be delivered immediately and will generate sales revenue of approximately 3 million SEK in the second quarter of 2017.

“Sales and marketing activities are now ongoing in many provinces and we see the new order as a confirmation that the interest in and demand for Bactiguard’s infection preventive solutions in China is great.” says Johan Rugfelt, COO.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2017-06-30, at. 08.00

For further information, please contact:

Johan Rugfelt, COO, mobile +46 708 724 739

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com